# Psychedelic-assisted therapy

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Therapy
Updated: 2026-10-15
Canonical: https://heretic.bio/articles/psychedelic-assisted-therapy.html

> Psychedelic-assisted therapy pairs a supervised drug session with preparation and integration psychotherapy. The evidence is promising but uneven: MDMA-assisted therapy reduced PTSD symptoms versus placebo-plus-therapy in Phase 2 and 3 trials with benefits held at 12 months, psilocybin has its strongest data in treatment-resistant depression and end-of-life anxiety, and ketamine is the only FDA-approved option. Key caveats are strict exclusion criteria, near-impossible blinding, and limited long-term safety data. MDMA and psilocybin remain Schedule I federally.

## Overview

**Psychedelic-Assisted Therapy (PAT)** combines the careful administration of psychedelic substances (MDMA, psilocybin, ketamine, and others) with psychotherapeutic support to treat mental health conditions, particularly **treatment-resistant PTSD, depression, and anxiety**. After decades of prohibition, this field is experiencing a renaissance of clinical research with remarkably promising results.

> _"MDMA may prove to be a breakthrough treatment for difficult cases of Post-Traumatic Stress Disorder."_

## Key Substances in Clinical Use

### MDMA-Assisted Therapy (MDMA-AT)

**Mechanism:** \- Increases serotonin, dopamine, and norepinephrine release \- Reduces activity in the **amygdala** (fear center), decreasing threat response \- Increases activity in the **prefrontal cortex** , enabling cognitive processing \- Enhances feelings of **trust, empathy, and connection** — creating optimal conditions for trauma processing \- Allows patients to revisit traumatic memories without being overwhelmed

**Evidence:** \- Multiple Phase 2 and Phase 3 trials show **significant reduction in PTSD symptoms** \- In MAPS-sponsored trials, PTSD symptom severity **significantly decreased more** for MDMA-AT vs. placebo + therapy \- Benefits maintained at 12-month follow-up \- Being studied for group therapy format (Dr. Christopher Stauffer, OHSU/Portland VA)

**Session structure:** \- Multiple preparatory sessions with therapists \- 2-3 MDMA sessions (8-hour sessions with two therapists present) \- Integration sessions between and after dosing sessions \- Total treatment course: ~12 weeks

* * *

### Psilocybin-Assisted Therapy (P-AT)

**Mechanism:** \- Active compound **psilocin** binds to serotonin 5-HT2A receptors \- Profoundly alters **default mode network (DMN)** activity — the brain network associated with ego/self-narrative \- Increases **brain connectivity** between normally segregated regions \- Creates a "reset" effect on rigid thought patterns

**Evidence for PTSD:** \- Researchers have begun pairing psilocybin with various forms of psychotherapy \- Showing promise for trauma-related conditions \- **Strongest evidence** for: treatment-resistant depression, end-of-life anxiety, substance use disorders

**Other applications:** \- Depression (including treatment-resistant) \- End-of-life anxiety and existential distress \- Alcohol and tobacco addiction \- OCD \- Cluster headaches

* * *

### Ketamine-Assisted Therapy

**Mechanism:** \- NMDA receptor antagonist \- Rapidly increases **BDNF** (brain-derived neurotrophic factor) — promoting neural plasticity \- Dissociative effects create psychological distance from traumatic material \- Can produce rapid antidepressant effects (within hours)

**Applications:** \- Treatment-resistant depression (strongest evidence) \- Suicidal ideation (rapid relief) \- PTSD (emerging evidence) \- Chronic pain

* * *

## The Therapeutic Framework

Psychedelic-assisted therapy is NOT simply "taking drugs." The therapeutic framework includes:

### 1\. Screening and Preparation

  * Rigorous medical and psychological eligibility criteria
  * Exclusion criteria: active psychosis, bipolar mania, certain cardiovascular conditions, pregnancy
  * Multiple preparation sessions to establish trust and set intentions
  * Teaching self-regulation skills



### 2\. The Medicine Session

  * Conducted in a comfortable, specially designed setting
  * Two trained therapists present throughout
  * Eye mask, curated music playlist
  * 6-8 hours (MDMA/psilocybin); 1-2 hours (ketamine)
  * Client is encouraged to turn inward and explore



### 3\. Integration

  * Processing the experience in follow-up therapy sessions
  * Journaling, art, movement
  * Implementing insights into daily life
  * Multiple integration sessions over weeks



## Current Research Landscape

Substance | Condition | Status  
---|---|---  
**MDMA** | PTSD | Phase 3 complete; seeking FDA approval  
**Psilocybin** | Depression | Phase 2/3; Oregon legalized  
**Psilocybin** | End-of-life anxiety | Phase 2 completed  
**Ketamine** | Depression | FDA-approved (Spravato)  
**MDMA** | Social anxiety (autism) | Phase 2  
**Psilocybin** | Substance use disorders | Phase 2  
  
## Important Considerations

### Limitations of Current Research

  * Studies use **rigorous exclusion criteria** — many people with PTSD don't qualify
  * **Masking challenges** — participants often know whether they received active drug or placebo
  * Long-term safety data still limited
  * Need more diverse participant populations



### Legal Status

  * **Varies by jurisdiction** — check local laws
  * MDMA and psilocybin remain Schedule I in the US (though this is changing)
  * Ketamine is legally available with prescription
  * Oregon and Colorado have legalized psilocybin in certain contexts
  * Clinical trials are available in many locations



### Risks

  * **Psychological distress** during sessions (manageable with trained therapists)
  * **Headaches** (especially with psilocybin)
  * **Blood pressure/heart rate elevation** (especially with MDMA)
  * **Potential for destabilization** in vulnerable individuals
  * **Contraindicated** for those with personal/family history of psychosis or bipolar disorder

## Sources